Have a feature idea you'd love to see implemented?
Let us know!
CRVO CervoMed Inc
Price (delayed)
$12.82
Market cap
$105.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.98
Enterprise value
$95.8M
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing
Highlights
CervoMed's EPS has surged by 88% YoY and by 72% QoQ
The company's quick ratio rose by 37% YoY
CRVO's net income is down by 21% QoQ and by 15% YoY
Key stats
What are the main financial stats of CRVO
Market
Valuations
Earnings
Shares outstanding
8.25M
Market cap
$105.81M
Enterprise value
$95.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.12
Price to sales (P/S)
11.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.92
Revenue
$9.65M
EBIT
-$5.04M
EBITDA
-$5.04M
Free cash flow
-$3.46M
Per share
Balance sheet
Liquidity
EPS
-$0.98
Free cash flow per share
-$0.4
Book value per share
$6.06
Revenue per share
$1.11
TBVPS
$6.11
Total assets
$53.19M
Total liabilities
$3.21M
Debt
$0
Equity
$49.98M
Working capital
$44.11M
Debt to equity
0
Current ratio
14.73
Quick ratio
14.03
Net debt/EBITDA
1.98
Margins
Efficiency
Dividend
EBITDA margin
-52.2%
Gross margin
100%
Net margin
-52.2%
Operating margin
-111.3%
Return on assets
-24.2%
Return on equity
-27.9%
Return on invested capital
-53.6%
Return on capital employed
-10.1%
Return on sales
-52.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVO stock price
How has the CervoMed stock price performed over time
Intraday
-2.95%
1 week
-6.36%
1 month
-19.77%
1 year
73.71%
YTD
68.02%
QTD
-12.19%
Financial performance
How have CervoMed's revenue and profit performed over time
Revenue
$9.65M
Gross profit
$9.65M
Operating income
-$10.75M
Net income
-$5.04M
Gross margin
100%
Net margin
-52.2%
CRVO's operating income has dropped by 139% year-on-year and by 20% since the previous quarter
The net margin has soared by 63% YoY
The operating margin has grown by 23% YoY
CRVO's net income is down by 21% QoQ and by 15% YoY
Growth
What is CervoMed's growth rate over time
Valuation
What is CervoMed stock price valuation
P/E
N/A
P/B
2.12
P/S
11.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.92
CervoMed's EPS has surged by 88% YoY and by 72% QoQ
The P/B is 76% below the last 4 quarters average of 9.1 and 22% below the 5-year quarterly average of 2.8
The stock's price to sales (P/S) is 22% more than its last 4 quarters average of 9.8
The revenue rose by 19% QoQ
Efficiency
How efficient is CervoMed business performance
The return on equity has surged by 66% year-on-year and by 39% since the previous quarter
CervoMed's return on sales has surged by 63% YoY
The company's return on invested capital rose by 46% YoY
The ROA has grown by 33% from the previous quarter and by 11% YoY
Dividends
What is CRVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVO.
Financial health
How did CervoMed financials performed over time
The total liabilities has soared by 119% YoY and by 21% from the previous quarter
The current ratio has grown by 38% YoY
The debt is 100% less than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.